Tempus Selected as Sequencing and Analytics Provider by the Prostate Cancer Clinical Trials Consortium for Phase II Clinical Trial

CHICAGO, Aug. 17, 2017 -- Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data announced today that it was selected by the Prostate Cancer Clinical Trials Consortium (PCCTC) to serve as a partner for its phase II clinical trial focused on identifying the most effective treatment for prostate cancer patients with genomic evidence of problems with DNA repair.

Tempus will be responsible for the sequencing and analytics for the study: A Randomized Phase II Trial of Abiraterone, Olaparib or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects. The study will screen 400 patients across over 20 participating centers.

“While progress has been made to improve the prognosis of those diagnosed with prostate cancer, castration-resistant prostate cancer is a particularly difficult type to treat,” said the study’s principal investigator and PCCTC member Dr. Maha Hussain of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. “We look forward to partnering with Tempus and learning from the genomic insights its technology will bring as we work to improve patient outcomes.”

With its growing network of investigators specializing in cutting-edge collaborative research, the PCCTC is one of the nation’s premier prostate cancer clinical trials group, driving critical efforts to translate scientific discoveries to improved standards of care.

“Tempus is pleased to work alongside the PCCTC in its efforts to bring more effective treatments to patients living with prostate cancer,” said Eric Lefkofsky, Founder and CEO at Tempus. “By bringing technology to the fight against cancer, we are confident that patient outcomes will improve.”

About Tempus:
Tempus is a technology company that is building the world’s largest library of molecular and clinical data and an operating system to make that data accessible and useful. We enable physicians to deliver personalized cancer care for patients through our interactive analytical and machine learning platform. We provide genomic sequencing services and analyze molecular and therapeutic data to empower physicians to make real-time, data-driven decisions. Our goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as we gather more data. For more information, visit tempus.com.

About the Prostate Cancer Clinical Trials Consortium (PCCTC):
In 2005, the Prostate Cancer Foundation and the Department of Defense (DOD) Prostate Cancer Research Program (PCRP) initiated the Prostate Cancer Clinical Trials Consortium (PCCTC) in response to gaps identified in prostate cancer clinical research by physician investigators and prostate cancer advocates. By establishing transparent project co-development between investigators, research sites and industry partners, the PCCTC has created a new paradigm for evaluating prostate cancer therapies. Uniform trial endpoints, the use of validated biomarkers, and the adaptation of the clinical states model of prostate cancer have further enabled accelerated drug development within the consortium. The PCCTC is now a major multi-institutional clinical research organization consisting of a nationwide network of physicians at over 20 academic institutions specializing in cutting-edge prostate cancer research. For more information, please visit www.pcctc.org.

Clo Ewing
Director of Communications at Tempus
[email protected]